bq 610 has been researched along with 15-keto-13,14-dihydroprostaglandin f2alpha in 1 studies
| Studies (bq 610) | Trials (bq 610) | Recent Studies (post-2010) (bq 610) | Studies (15-keto-13,14-dihydroprostaglandin f2alpha) | Trials (15-keto-13,14-dihydroprostaglandin f2alpha) | Recent Studies (post-2010) (15-keto-13,14-dihydroprostaglandin f2alpha) |
|---|---|---|---|---|---|
| 124 | 1 | 3 | 678 | 46 | 50 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoagland, TA; Keator, CS; McCracken, JA; Milvae, RA; Schreiber, DT | 1 |
1 trial(s) available for bq 610 and 15-keto-13,14-dihydroprostaglandin f2alpha
| Article | Year |
|---|---|
Intrauterine infusion of BQ-610, an endothelin type A receptor antagonist, delays luteolysis in dairy heifers.
Topics: Administration, Intravaginal; Animals; Cattle; Dinoprost; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Estrous Cycle; Female; Luteolysis; Oligopeptides; Progesterone; Time Factors; Uterus | 2008 |